Image de couverture de livre

Five‐Grass‐Pollen Sublingual Immunotherapy Drops Are Efficacious and Well Tolerated in Adults: The RHAPSODY Phase III Trial

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Alain Didier, Ruta Gronskyte Juhl, Terrie Dalgaard, Antoine Chartier, Philippe Devillier
Format:	Artículo Open Access
Publié:	Wiley 2025
Sujets:	Allergy
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Low‐Dose Intralymphatic Immunotherapy for Grass Pollen Allergy is Both Safe and Effective
par: Bjarke Hviid‐Vyff, et autres
Publié: (2025)

Meta‐Analysis of PQ Grass 27600 SU Efficacy and Quality of Life From Phase III Trials
par: Stefan Zielen, et autres
Publié: (2025)

Real‐Life Safety of Japanese Cedar Pollen Sublingual Immunotherapy Tablets: A Post‐Marketing Survey
par: Minoru Gotoh, et autres
Publié: (2026)

Efficacy and Safety of Subcutaneous vs. Sublingual Immunotherapy in Allergic Rhinitis: A Systematic Review and Meta‐Analysis
par: Shambo Samrat Samajdar, et autres
Publié: (2024)

Real‐World Effectiveness for Sublingual Allergen Immunotherapy Among School‐Aged Children and Adolescents
par: Yusuke Okubo, et autres
Publié: (2025)

Preventive Application of House Dust Mite‐Sublingual Immunotherapy Induces Blocking Antibodies in Sensitized Preschool Children
par: Varsha Dwivedi, et autres
Publié: (2026)

The SQ tree sublingual immunotherapy tablet is effective and well tolerated in children—A pivotal phase III trial
par: Monika Gappa, et autres
Publié: (2024)

Adherence to Grass Pollen Allergen Immunotherapy and Allergy Medication Use in Patients With Allergic Rhinitis
par: Morten Borg, et autres
Publié: (2025)

Clinical Benefits of a Randomized Allergy App Intervention in Grass Pollen Sufferers: A Controlled Trial
par: Caroline Holzmann, et autres
Publié: (2025)

Biphasic Effects on Allergen‐Specific Type 2 Memory B Cells Over 18 Months Sublingual Immunotherapy for House Dust Mite Allergy
par: Lin Hsin, et autres
Publié: (2026)

Peanut Component‐Specific IgE and IgG4 Are Modulated by Sublingual Immunotherapy and Are Associated With Remission in 1–4‐Year‐Old Children
par: Neel Singh, et autres
Publié: (2025)

The Drop of Allergen Immunotherapy for Respiratory Allergy in Italy: An Assessment of Sales
par: Mattia Giovannini, et autres
Publié: (2025)

A One‐Strength Dose Escalation Regimen for Birch Pollen SCIT Is Safe and Tolerable in Children, Adolescents, and Adults
par: Marek Jutel, et autres
Publié: (2026)

Efficacy and Safety Profile of Animal Dander Immunotherapy: A Multicentre UK Study
par: Da‐In S. Kim, et autres
Publié: (2025)

Circulating Type 2 Memory B Cell Frequency Is a Biomarker for Allergen Immunotherapy Efficacy in Patients With Allergic Rhinitis
par: Yue Ma, et autres
Publié: (2026)

Dupilumab Improves Clinical Symptoms and Biomarkers in Comorbid Seasonal Timothy Grass Pollen Allergic Rhinitis in Patients With CRSwNP
par: Caroline Beutner, et autres
Publié: (2024)

A Walk in the Park: Influence of Natural Co‐Exposure to Grass Pollen and Fungal Spores on Nasal Mycobiome and Cytokine Responses
par: Annika Eggestein, et autres
Publié: (2026)

Safety and Efficacy of Very Low‐Dose Multi‐Nut Oral Immunotherapy in Children
par: Julia E. M. Upton, et autres
Publié: (2025)

Oral Peanut Immunotherapy With Butyrate Adjuvant ( OPIA ) in Children: A Randomised, Controlled Trial
par: Peter S. Hsu, et autres
Publié: (2025)

Allergen‐Specific Immunotherapy and Trained Immunity
par: Leticia Martín‐Cruz, et autres
Publié: (2024)

Algorithms of Patient Selection for Allergen Immunotherapy
par: U. Petra Zieglmayer, et autres
Publié: (2026)

Three‐Year Longitudinal Evaluation of Timing Effects on Subcutaneous Immunotherapy Efficacy and Safety in Allergic Rhinitis
par: Hang Li, et autres
Publié: (2025)

Diversity and Dosage Determine the Efficacy of the Probiotic SYN ‐53 in Allergic Rhinoconjunctivitis: A Randomized, Double‐Blind, Placebo‐Controlled Trial
par: Karl‐Christian Bergmann, et autres
Publié: (2025)

Response to Correspondence to “Short‐course subcutaneous treatment with PQ Grass strongly improves symptom and medication scores in grass allergy”
par: P. J. de Kam, et autres
Publié: (2024)

Pragmatic Low‐Dose Oral Immunotherapy for Preschool Children With Peanut Allergy: A Randomised Controlled Trial
par: Michael O'Sullivan, et autres
Publié: (2025)

Correspondence: First Peanut ( Arachis hypogaea ) Allergen Oral Immunotherapy Product Out of Sale—A Major Drawback for Food Allergy Immunotherapy?
par: S. Arasi, et autres
Publié: (2026)

Efficacy and Safety of Stapokibart in Adults With Moderate‐to‐Severe Atopic Dermatitis With and Without Type 2 Comorbidities: A Post Hoc Analysis of a Phase 3 Trial
par: Yan Zhao, et autres
Publié: (2025)

A Pilot Randomised Controlled Dose‐Ranging Trial of Ant Venom Immunotherapy With and Without Delta‐Inulin Adjuvant
par: Thanh‐Thao Adriana Le, et autres
Publié: (2026)

The Minimal Clinically Important Difference in Allergen Immunotherapy: An Evidence‐Based Approach
par: Oliver Pfaar, et autres
Publié: (2025)

Cost‐Effectiveness of Allergen Immunotherapy for Allergic Rhinitis: A Systematic Review
par: Joshua Jacob, et autres
Publié: (2026)

Efficacy and Safety of Ligelizumab in Individuals With Confirmed Peanut Allergy
par: Philippe Bégin, et autres
Publié: (2026)

Algorithms in Allergy: General Allergen Molecule‐Based Algorithm for Allergen‐Specific Immunotherapy
par: Huey‐Jy Huang, et autres
Publié: (2026)

Cost‐Effectiveness of Venom Immunotherapy in Preventing Severe Bee and Wasp Sting Reactions
par: Gunter Sturm, et autres
Publié: (2025)

Effects of Butyrylated High Amylose Maize Starch ( HAMSB ) as an Adjuvant for Oral Immunotherapy
par: Duan Ni, et autres
Publié: (2025)

Oral Immunotherapy of Peanut Allergy: A Critical Role for Gut‐Associated Immunity
par: A. Kuehn, et autres
Publié: (2025)

Corrigendum to “Immune Regulation by Intralymphatic Immunotherapy With Modular Allergen Translocation MAT Vaccine”
Publié: (2025)

Codfish Oral Immunotherapy in Children Aged 2–10: Randomized Placebo‐Controlled Study
par: Agnes Sze‐yin Leung, et autres
Publié: (2026)

Efficacy and Safety of Omalizumab Combined With Allergen Immunotherapy in Children With Moderate to Severe Allergic Asthma: Limitations and Future Directions
par: Yitong Weng, et autres
Publié: (2025)

Early Changes in House Dust Mite Component Specific Immunoglobulin Levels Predict the One‐Year Efficacy of Allergen Immunotherapy in Patients With Allergic Rhinitis
par: Shuying Li, et autres
Publié: (2025)

Oral Immunotherapy Induces Shift in lncRNA Expression Modulating Allergen‐Specific Immune Responses
par: Olivia Liong, et autres
Publié: (2025)